OP40
Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10)
liquid, clone RAS 10, Calbiochem®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
RAS 10, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human, mouse, rat
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
isotype
IgG2a
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... KRAS(3845)
General description
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 myeloma cells (see application references). Recognizes the ~21 kDa Ras protein.
Recognizes the ~21 kDa H-, K-, and N-Ras proteins in SW480 and Y1 cells and breast carcinoma tissue.
This Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10) is validated for use in FC, Frozen Sections, Immunoblotting, IF, IP, Paraffin Sections for the detection of Pan-Ras (Ab-3).
Immunogen
recombinant human p21 Ras
Application
Flow Cytometry (2.5 g/ml)
Frozen Sections (2.5 g/ml)
Immunoblotting (0.1-3 g/ml, chemiluminescent and colorimetric, see application references)
Immunofluorescence (2.5 g/ml, see application references)
Immunoprecipitation (1 g/sample)
Paraffin Sections (2.5 g/ml, saponin pre-treatment required)
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Analysis Note
Positive Control
SW480 or Y1 cells or breast carcinoma tissue
SW480 or Y1 cells or breast carcinoma tissue
Other Notes
Rodenhuis, S. et al., 1992. Cancer Res. (Suppl)52, 2665s.
Sidransky, D., et al. 1992. Science256, 102.
Hamer, P.J., et al. 1990. Hybridoma9, 573.
Bos, J.L. 1989. Cancer Res.49, 4682.
Furth, M. E., et al. 1987. Oncogene1, 47.
Kraus, M.H., et al. 1984. Proc. Natl. Acad. Sci. USA81, 5384.
Shimizu, K., et al. 1983. Proc. Natl. Acad. Sci. USA80, 2112.
Taparowsky, E., et al. 1983. Cell34, 581.
Ellis, R.W., et al. 1981. Nature292, 506.
Shih, T.Y., et al. 1980. Nature287, 686.
Sidransky, D., et al. 1992. Science256, 102.
Hamer, P.J., et al. 1990. Hybridoma9, 573.
Bos, J.L. 1989. Cancer Res.49, 4682.
Furth, M. E., et al. 1987. Oncogene1, 47.
Kraus, M.H., et al. 1984. Proc. Natl. Acad. Sci. USA81, 5384.
Shimizu, K., et al. 1983. Proc. Natl. Acad. Sci. USA80, 2112.
Taparowsky, E., et al. 1983. Cell34, 581.
Ellis, R.W., et al. 1981. Nature292, 506.
Shih, T.Y., et al. 1980. Nature287, 686.
The level of expression of p21ras is variable in different tissues. For this reason we recommend a concentration step prior to immunoblot analysis to obtain optimal results. Antibody should be titrated for optimal results in individual systems.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The Journal of biological chemistry, 274(44), 31588-31592 (1999-10-26)
The activity of the catalytic domain of the orphan MAP kinase ERK5 is increased by Ras but not Raf-1 in cells, which suggests that ERK5 might mediate Raf-independent signaling by Ras. We found that Raf-1 does contribute to Ras activation
The Journal of biological chemistry, 273(7), 3854-3860 (1998-03-28)
Extracellular signal-regulated protein kinase 5 (ERK5) is a recently discovered orphan mitogen-activated protein kinase for which no substrates or strong activators have been described. Two ERK5 chimeras were created as a novel approach to discover its substrates and upstream regulators.
Cells, 9(1) (2020-01-08)
The adenoviral early region 1A (E1A) protein has proapoptotic and angiogenic activity, along with its chemosensitizing effect, making it the focus of increased interest in the context of cancer therapy. It was previously shown that E1A-induced chemosensitization to different drugs
Translational oncology, 14(1), 100880-100880 (2020-10-20)
Ras mutations are present in only a subset of sporadic human cutaneous squamous cell carcinomas (cSCC) even though Ras is activated in most. This suggests that other mechanisms of Ras activation play a role in the disease. The aberrant expression
Cell reports, 24(11), 2869-2882 (2018-09-13)
Cerebrovascular malformations (CVMs) affect approximately 3% of the population, risking hemorrhagic stroke, seizures, and neurological deficits. Recently Ras mutations have been identified in a majority of brain arterio-venous malformations. We generated an endothelial-specific, inducible HRASV12 mouse model, which results in
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service